Journal Article

DKFZ-2021-01159

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.

Salwender, H. ; Elmaagacli, A. ; Merz, M. ; Miah, K.DKFZ* ; Benner, A.DKFZ* ; Haenel, M. ; Jehn, C. ; Mai, E. K. ; Bertsch, U. ; Blau, I. W. ; Scheid, C. ; Hose, D. ; Seckinger, A. ; Jauch, A. ; Raab, M. S. ; Luntz, S. P. ; Besemer, B. ; Munder, M. ; Brossart, P. ; Fuhrmann, S. ; Lindemann, H.-W. ; Weisel, K. ; Duerig, J. ; Goldschmidt, H.

2021
Springer Nature London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41375-021-01298-y

Note: 2021 Oct;35(10):3007-3011

---

Contributing Institute(s):

1. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2021

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---